Our Drug Candidates

UroGen is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC.  In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.



MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma (UTUC), an urothelial cancer in the upper tract. UroGen has received Orphan Drug Designations from the FDA for MitoGel for the treatment of UTUC.


VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).


Vesimune is a new formulation of the TLR7 agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ (CIS), a high-grade form of NMIBC. UroGen has received Orphan Drug Designation from the FDA for Vesimune for the treatment of CIS.


BotuGel is a novel intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC).  The Company recently licensed the BotuGel program to Allergan for further development.